Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sagent Pharmaceuticals, Inc. (SGNT)

NEW YORK, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sagent Pharmaceuticals, Inc. ("Sagent" or the "Company") (Nasdaq: SGNT) in the United States District Court for the Northern District of Illinois on behalf of current stock holders of Sagent, seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act").

On July 10, 2016, Sagent's Board of Directors (the "Board") caused Sagent to enter into an agreement and plan of merger with Nichi-Iko Pharmaceutical Co., Ltd. (TSE:4541) and its subsidiary Shepard Vision, Inc.  (the "Merger Agreement").  Pursuant to the terms of the Merger Agreement, stockholders of Sagent will receive $21.75 per share in cash.  The Complaint alleges that on August 1, 2016, Defendants issued materially incomplete and misleading disclosures in the Solicitation/Recommendation Statement filed on Schedule 14D-9 (the "Solicitation Statement") filed with the United States Securities and Exchange Commission ("SEC") in connection with the Proposed Transaction.  According to the Complaint, the Solicitation Statement is deficient and misleading in that it fails to provide adequate disclosure of all material information related to the Proposed Transaction.

If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com.

Please visit our website at http://www.gme-law.com for more information about the firm.